NCAM1

Across TCGA pan-cancer cohorts, NCAM1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NCAM1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NCAM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCAM1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where NCAM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	13	view →
LUAD	DFS	Median	II,III,IV	0.713	0.947	.004	8	view →
PDAC	OS	Quartile	III,IV	0.993	0.582	.017	4	view →
GBM	DFS	Quartile	All	0.903	0.691	.013	3	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →
LSCC	DFS	Median	II,III,IV	0.864	0.969	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NCAM1–CCRCC (DFS)

Open the CCRCC breakdown →